12月19日 - ** 总部位于丹麦的药物开发商Evaxion EVAX.O股价盘前下跌1.2%至5.68美元
** 称默克公司MRK.N将不会行使其对Evaxion的试验性淋病疫苗EVX-B2的许可选择权，从而使EVAX拥有该项目全球权利
** Evaxion 表示将寻找另一个潜在的许可合作伙伴
** 今年早些时候，默克公司行使了其对Evaxion公司另一种候选疫苗EVX-B3的选择权，根据该协议，Evaxion公司可获得高达5.92亿美元的里程碑付款和特许权使用费。
** Evaxion公司补充说，默克公司的决定不会影响其现金流，该现金流将持续到2027年下半年。
** 截至上一交易日收盘，EVAX年累计上涨36%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.